Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cancer Res. 2021 May 3;81(13):3607–3620. doi: 10.1158/0008-5472.CAN-20-3790

Figure 1. Depletion of DDX3X upregulates genes in the antiviral innate immune response.

Figure 1.

A. KM-plotter analysis shows that mRNA and protein levels of DDX3X are associated with a poor survival outcome in breast cancer. Overall survival (pan-cancer RNA seq), OS; Post- Progression Survival, PPS.

B. Genome-wide transcriptome analysis in DDX3X-control (shNS) or -knockdown (shDDX3X) MCF7 cells using a next-generation RNA deep sequencing. Differentially expressed genes (DEGs) (FDR 0.05, fold change >1.5 or < −1.5) in shNS vs. shDDX3X are shown in an MA-plot (labeled in red) and in a heat map.

C. Top canonical pathways of DEGs between DDX3X-control and -knockdown (KD) MCF7 cells.

D. GSEA analysis of DEGs between DDX3X-control and -KD MCF7 cells.

E. qRT-PCR of ISGs and APP gene expression in DDX3X-control or -KD MCF7 cells.

A non-specific shRNA (shNS); DDX3X targeting shRNAs (shDDX3X). Data are representative of three independent experiments. Statistical significance was calculated using unpaired t-tests. *p < 0.05; **p<0.01; ***p < 0.001; ****p < 0.0001; ns, not significant.